Resistance of tumor cells to cytolytic T lymphocytes involves Rho-GTPases and focal adhesion kinase activation. 2008

Soraya Abouzahr-Rifai, and Meriem Hasmim, and Habib Boukerche, and Jocelyne Hamelin, and Bassam Janji, and Abdelali Jalil, and Claudine Kieda, and Fathia Mami-Chouaib, and Jacques Bertoglio, and Salem Chouaib
Institut Gustave Roussy, INSERM U753, 94800 Villejuif, France.

Tumor cells evade adaptive immunity by a variety of mechanisms, including selection of variants that are resistant to specific cytotoxic T lymphocyte (CTL) pressure. Recently, we have reported that the reorganization of the actin cytoskeleton can be used by tumor cells as a strategy to promote their resistance to CTL-mediated lysis. In this study, we further examined the functional features of a CTL-resistant tumor variant and investigated the relationship between cytoskeleton alteration, the acquisition of tumor resistance to CTL-induced cell death, Rho-GTPases, and focal adhesion kinase (FAK) pathways. Our data indicate that although the resistant cells do not display an increased migratory potential, an alteration of adhesion to the extracellular matrix was observed. When Rho-GTPases were activated in cells by the bacterial CNF1 (cytotoxic necrotizing factor 1), striking changes in the cell morphology, including actin cytoskeleton, focal adhesions, and membrane extensions, were observed. More importantly, such activation also resulted in a significant attenuation of resistance to CTL-induced cell death. Furthermore, we demonstrate that FAK signaling pathways were constitutively defective in the resistant cells. Silencing of FAK in the sensitive target cells resulted in the inhibition of immune synapse formation with specific CTLs and their subsequent lysis. Expression of the FAK mutant (Y397F) resulted in an inhibition of IGR-Heu cell adhesion and of their susceptibility to specific lysis. These results suggest that FAK activation plays a role in the control of tumor cell susceptibility to CTL-mediated lysis.

UI MeSH Term Description Entries
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005109 Extracellular Matrix A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere. Matrix, Extracellular,Extracellular Matrices,Matrices, Extracellular
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015971 Gene Expression Regulation, Enzymologic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in enzyme synthesis. Enzymologic Gene Expression Regulation,Regulation of Gene Expression, Enzymologic,Regulation, Gene Expression, Enzymologic

Related Publications

Soraya Abouzahr-Rifai, and Meriem Hasmim, and Habib Boukerche, and Jocelyne Hamelin, and Bassam Janji, and Abdelali Jalil, and Claudine Kieda, and Fathia Mami-Chouaib, and Jacques Bertoglio, and Salem Chouaib
October 2000, Journal of cell science,
Soraya Abouzahr-Rifai, and Meriem Hasmim, and Habib Boukerche, and Jocelyne Hamelin, and Bassam Janji, and Abdelali Jalil, and Claudine Kieda, and Fathia Mami-Chouaib, and Jacques Bertoglio, and Salem Chouaib
November 1999, European journal of immunology,
Soraya Abouzahr-Rifai, and Meriem Hasmim, and Habib Boukerche, and Jocelyne Hamelin, and Bassam Janji, and Abdelali Jalil, and Claudine Kieda, and Fathia Mami-Chouaib, and Jacques Bertoglio, and Salem Chouaib
April 2011, Diabetes,
Soraya Abouzahr-Rifai, and Meriem Hasmim, and Habib Boukerche, and Jocelyne Hamelin, and Bassam Janji, and Abdelali Jalil, and Claudine Kieda, and Fathia Mami-Chouaib, and Jacques Bertoglio, and Salem Chouaib
May 2000, Journal of neurochemistry,
Soraya Abouzahr-Rifai, and Meriem Hasmim, and Habib Boukerche, and Jocelyne Hamelin, and Bassam Janji, and Abdelali Jalil, and Claudine Kieda, and Fathia Mami-Chouaib, and Jacques Bertoglio, and Salem Chouaib
February 2019, Journal of experimental & clinical cancer research : CR,
Soraya Abouzahr-Rifai, and Meriem Hasmim, and Habib Boukerche, and Jocelyne Hamelin, and Bassam Janji, and Abdelali Jalil, and Claudine Kieda, and Fathia Mami-Chouaib, and Jacques Bertoglio, and Salem Chouaib
February 2012, Immunology letters,
Soraya Abouzahr-Rifai, and Meriem Hasmim, and Habib Boukerche, and Jocelyne Hamelin, and Bassam Janji, and Abdelali Jalil, and Claudine Kieda, and Fathia Mami-Chouaib, and Jacques Bertoglio, and Salem Chouaib
August 2000, Japanese journal of cancer research : Gann,
Soraya Abouzahr-Rifai, and Meriem Hasmim, and Habib Boukerche, and Jocelyne Hamelin, and Bassam Janji, and Abdelali Jalil, and Claudine Kieda, and Fathia Mami-Chouaib, and Jacques Bertoglio, and Salem Chouaib
January 2005, Journal of cellular and molecular medicine,
Soraya Abouzahr-Rifai, and Meriem Hasmim, and Habib Boukerche, and Jocelyne Hamelin, and Bassam Janji, and Abdelali Jalil, and Claudine Kieda, and Fathia Mami-Chouaib, and Jacques Bertoglio, and Salem Chouaib
December 1999, Journal of cell science,
Soraya Abouzahr-Rifai, and Meriem Hasmim, and Habib Boukerche, and Jocelyne Hamelin, and Bassam Janji, and Abdelali Jalil, and Claudine Kieda, and Fathia Mami-Chouaib, and Jacques Bertoglio, and Salem Chouaib
October 2003, The Journal of biological chemistry,
Copied contents to your clipboard!